Literature DB >> 14192554

ERYTHROCYTE SENSITIZATION BY BLOOD GROUP-SPECIFIC BACTERIAL ANTIGENS.

G F SPRINGER, R E HORTON.   

Abstract

Human and chicken erythrocytes are readily coated in vitro by blood group active protein-lipopolysaccharides and lipopolysaccharides from E. coli O(86) and E. coli O(128). Serum albumin, alpha(2)- and beta-lipoproteins inhibit this sensitization. Blood group B specific agglutination of erythrocytes with B or B-like antigens was obtained with antibodies purified by adsorption on and elution from B erythrocytes. Anti-blood group B and E. coli O(86)-specific antibodies could be eluted from E. coli O(86)-coated O erythrocytes. Eel anti-H(O) serum agglutinated O erythrocytes and only those A(1)B red cells which were coated with blood group H(O) active E. coli products. Blood group active substances specifically inhibited agglutination of lipopolysaccharide-coated erythrocytes by anti-B and anti-H(O) agglutinins. Demonstrable amounts of lipopolysaccharide could only be removed from coated erythrocytes by washing them at elevated temperatures (58 degrees C) in physiological solutions. Red cell sensitization with B active E. coli O(86) substances was achieved in vivo in a minority of severely diseased infants and in germ-free and ordinary chicks which were in tourniquet shock after treatment with cathartics. Therefore, a possible mode by which erythrocytes of patients with severe intestinal disorders acquire antigens is the fixation of bacterial substances to their surfaces, if there are not enough of the normally interfering plasma factors present.

Entities:  

Keywords:  ANEMIA; ANTIGENS; BLOOD GROUPS; CLINICAL RESEARCH; DIARRHEA, INFANTILE; ERYTHROCYTES; ESCHERICHIA COLI; EXPERIMENTAL LAB STUDY; HEMAGGLUTINATION INHIBITION TESTS; INFANT; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; LIPOPOLYSACCHARIDES; POULTRY

Mesh:

Substances:

Year:  1964        PMID: 14192554      PMCID: PMC2195380          DOI: 10.1085/jgp.47.6.1229

Source DB:  PubMed          Journal:  J Gen Physiol        ISSN: 0022-1295            Impact factor:   4.086


  15 in total

1.  IMMUNOCHEMICAL STUDIES ON BLOOD GROUPS. XXXI. DESTRUCTION OF BLOOD GROUP A ACTIVITY BY AN ENZYME FROM CLOSTRIDIUM TERTIUM WHICH DEACETYLATES N-ACETYLGALACTOSAMINE IN INTACT BLOOD GROUP SUBSTANCES.

Authors:  D M MARCUS; E A KABAT; G SCHIFFMAN
Journal:  Biochemistry       Date:  1964-03       Impact factor: 3.162

2.  Effects of lecithin, cholesterol, and serum on erythrocyte modification and antibody neutralization by enterobacterial lipopolysaccharides.

Authors:  E NETER; O WESTPHAL; O LUDERITZ
Journal:  Proc Soc Exp Biol Med       Date:  1955-03

3.  Acquisition of blood-group B-like bacterial antigens by human A and O erythrocytes.

Authors:  G F SPRINGER; N J HAHN
Journal:  Bibl Haematol       Date:  1962

4.  A weak B antigen, probably acquired.

Authors:  C M GILES; A E MOURANT; D M PARKIN; J F HORLEY; K J TAPSON
Journal:  Br Med J       Date:  1959-07-11

5.  The in vivo sensitization of avian erythrocytes with Salmonella gallinarum polysaccharide.

Authors:  A BUXTON
Journal:  Immunology       Date:  1959-07       Impact factor: 7.397

6.  A new elution technique for the preparation of specific immune anti-Rh serum.

Authors:  G A KELSALL; G H VOS
Journal:  Br J Haematol       Date:  1956-10       Impact factor: 6.998

7.  [Role of lipids in the sensitization of erythrocytes by tuberculin constituents].

Authors:  S V BOYDEN; P GRABAR
Journal:  Ann Inst Pasteur (Paris)       Date:  1954-09

8.  Blood group mucoids: their distribution and growth-promoting properties for Lactobacillus bifidus var. Penn.

Authors:  G F SPRINGER; C S ROSE; P GYORGY
Journal:  J Lab Clin Med       Date:  1954-04

9.  SEROLOGICAL STUDIES ON THE BLOOD OF THE PRIMATES : II. THE BLOOD GROUPS IN ANTHROPOID APES.

Authors:  K Landsteiner; C P Miller
Journal:  J Exp Med       Date:  1925-11-30       Impact factor: 14.307

10.  BLOOD GROUP ACTIVITY OF GRAM-NEGATIVE BACTERIA.

Authors:  G F Springer; P Williamson; W C Brandes
Journal:  J Exp Med       Date:  1961-06-01       Impact factor: 14.307

View more
  12 in total

1.  Specific inhibition of endotoxin coating of red cells by a human erythrocyte membrane component.

Authors:  G F Springer; S V Huprikar; E Neter
Journal:  Infect Immun       Date:  1970-01       Impact factor: 3.441

2.  A working hypothesis for the etiology and pathogenesis of nonspecific inflammatory bowel disease.

Authors:  R G Shorter; K A Huizenga; R J Spencer
Journal:  Am J Dig Dis       Date:  1972-11

3.  On the origin of anti-Thomsen-Friedenreich (T) antibodies.

Authors:  G F Springer; H Tegtmeyer
Journal:  Naturwissenschaften       Date:  1980-06

4.  Endotoxin-binding substances from human leukocytes and platelets.

Authors:  G F Springer; J C Adye
Journal:  Infect Immun       Date:  1975-11       Impact factor: 3.441

5.  Blood group isoantibody stimulation in man by feeding blood group-active bacteria.

Authors:  G F Springer; R E Horton
Journal:  J Clin Invest       Date:  1969-07       Impact factor: 14.808

6.  Pathogenicity ofAeromonas hydrophila in red leg disease in frogs.

Authors:  M M Rigney; J W Zilinsky; M A Rouf
Journal:  Curr Microbiol       Date:  1978       Impact factor: 2.188

7.  Experimental induction of an immunohaemolytic anaemia in the chicken with Salmonella gallinarum endotoxin.

Authors:  R K Assoku; W J Penhale
Journal:  Can J Comp Med       Date:  1978-01

8.  Localization of gonococcal lipopolysaccharide and its relationship to toxic damage in human fallopian tube mucosa.

Authors:  M D Cooper; P A McGraw; M A Melly
Journal:  Infect Immun       Date:  1986-02       Impact factor: 3.441

9.  Role of human cell surface structures in interactions between man and microbes.

Authors:  G F Springer
Journal:  Naturwissenschaften       Date:  1970-04

10.  Catfish antibodies to blood group substances. I. Response of the Australian freshwater catfish, Tandanus tandanus (Mitchell), to the injection of human A, B and H secretor materials.

Authors:  B A Baldo; B Boettcher
Journal:  Immunology       Date:  1971-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.